Continued R&D on KIBIT
First written in FY2016. 20 of 23 entries say "Restated". Latest entry: FY2026-H1.
47 other companies' latest entry also says "Restated".
- FY2026-H1RestatedAnnual report
「Total R&D expenses for the current interim consolidated accounting period were ¥142.954 million. The company is expanding new solutions and developing products to further improve the usability of its proprietary specialized AI, “KIBIT,” across a wide range of fields, including drug discovery support, diagnostic support, economic security, finance, and HR and sales support.」
The company continued deploying KIBIT in drug discovery, diagnostics, economic security, finance, and HR and sales support, as well as developing products, and disclosed R&D expenses of ¥142.954 million for the current interim consolidated accounting period. - FY2025RestatedAnnual report
「The company is developing new solutions and products to further improve the usability of its proprietary specialized AI, “KIBIT,” across a wide range of fields, including drug discovery support, diagnostic support, economic security, finance, and HR and sales support. Total R&D expenses incurred by the group during the current consolidated fiscal year were ¥75.561 million.」
The company continued expanding KIBIT across multiple fields and developing products. R&D expenses were disclosed as ¥75.561 million. - FY2024-Q3RestatedAnnual report
「Total R&D expenses for the cumulative third quarter of the current consolidated fiscal year were ¥146.935 million. The company is expanding new solutions and developing products to further improve the usability of its proprietary artificial intelligence engine, “KIBIT,” across a wide range of fields, including drug discovery support, diagnostic support, economic security, finance, and HR and sales support.」
The company continued deploying KIBIT in drug discovery, diagnostics, economic security, finance, and HR and sales support, as well as developing products, and recorded R&D expenses of ¥146.935 million. - FY2024-Q2RestatedAnnual report
「Total R&D expenses for the cumulative second quarter of the current consolidated fiscal year were ¥111.666 million.」
The company continued R&D aimed at deploying KIBIT in drug discovery, diagnostics, economic security, finance, and HR and sales support, and recorded R&D expenses of ¥111.666 million. - FY2024-Q1RestatedAnnual report
「Total R&D expenses for the cumulative first quarter of the current consolidated fiscal year were ¥63.317 million. The company is expanding new solutions and developing products to further improve the usability of its proprietary artificial intelligence engine, “KIBIT,” across a wide range of fields, including drug discovery support, diagnostic support, economic security, finance, and HR and sales support.」
The company continued expanding KIBIT across multiple fields and developing solutions and products, and disclosed first-quarter R&D expenses of ¥63.317 million. - FY2023-Q3RestatedAnnual report
「We are expanding solutions and developing products to further improve the usability of our proprietary artificial intelligence engines, KIBIT, Concept Encoder and Looca Cross, in a range of fields, including drug discovery support, diagnostic support, economic security, finance, human resources and sales support.」
The company continued deploying its 3 AI engines in drug discovery, diagnostics, economic security, finance, and HR and sales support, while expanding its solutions and developing products. R&D expenses were ¥153.854 million. - FY2022-Q3AdvancedAnnual report
「We are expanding solutions and developing products to further improve the usability of our proprietary artificial intelligence engines, KIBIT, Concept Encoder and Looca Cross, in a range of fields, including drug discovery support, diagnostic support, economic security, finance, human resources and sales support.」
Continued research and development to deploy 3 AI engines in drug discovery, diagnostics and economic security, among other fields. Research and development expenses for the cumulative third-quarter period were ¥132.424 million. - FY2021AdvancedAnnual report
「We are expanding solutions and developing products to further improve the usability of our proprietary artificial intelligence engines, KIBIT and Concept Encoder, in a range of fields, including drug discovery support, diagnostic support, finance, human resources and sales support. Research and development expenses incurred by our group during the consolidated fiscal year totaled ¥154.13 million.」
Continued research and development and expanded applications of KIBIT and Concept Encoder. Research and development expenses were ¥154.13 million. - FY2021-Q3RestatedAnnual report
「Research and development expenses for the cumulative third-quarter period totaled ¥116.436 million. We are expanding solutions and developing products to further improve the usability of our proprietary artificial intelligence engines, KIBIT and Concept Encoder, in a range of fields, including drug discovery support, diagnostic support, finance, human resources and sales support.」
Continued expanding the applications of KIBIT and Concept Encoder and developing products across various fields. Research and development expenses for the cumulative third-quarter period were ¥116.436 million. - FY2021-Q2RestatedAnnual report
「Research and development expenses for the cumulative second-quarter period totaled ¥91.524 million. We are expanding solutions and developing products to further improve the usability of our proprietary artificial intelligence engines, KIBIT and Concept Encoder, in a range of fields, including drug discovery support, diagnostic support, financial services, human resources and sales support.」
Continued expanding the applications of KIBIT and Concept Encoder and developing products, and recognized cumulative research and development expenses of ¥91.524 million for the second quarter. - FY2020-Q2RestatedAnnual report
「Research and development expenses for the cumulative second-quarter period totaled ¥35.892 million.」
Continued expanding solutions and developing products to improve KIBIT's usability in the legal tech AI and AI solutions businesses, and recognized research and development expenses of ¥35.892 million. - FY2020-Q1RestatedAnnual report
「Research and development expenses for the cumulative first-quarter period totaled ¥13.867 million.」
Continued expanding solutions and developing products to improve KIBIT's usability in the legal tech AI and AI solutions businesses. Research and development expenses were ¥13.867 million. - FY2019RestatedAnnual report
「We are expanding solutions and developing products to further improve the usability of our proprietary artificial intelligence engine, KIBIT, in the legal tech AI and AI solutions businesses. Research and development expenses incurred by our group during the consolidated fiscal year totaled ¥62.364 million.」
Continued expanding KIBIT solutions and developing products, and disclosed annual research and development expenses of ¥62.364 million. - FY2019-Q2RestatedAnnual report
「Research and development expenses for the cumulative second-quarter period totaled ¥35.44 million. We are expanding solutions and developing products to apply our proprietary artificial intelligence engine, KIBIT, in the digital marketing, healthcare and business intelligence fields. We are also continuing to develop Concept Encoder, our group's second proprietary artificial intelligence engine, for application in healthcare.」
Continued expanding KIBIT's applications and developing products, as well as developing Concept Encoder, and recognized research and development expenses of ¥35.44 million. - FY2019-Q1RestatedAnnual report
「Research and development expenses for the cumulative first-quarter period totaled ¥21.827 million.」
Continued expanding KIBIT solutions and developing products, as well as developing Concept Encoder. Disclosed research and development expenses of ¥21.827 million. - FY2018RestatedAnnual report
「We are expanding solutions and developing products to apply our proprietary artificial intelligence engine, KIBIT, in the digital communications, healthcare and business intelligence fields. Research and development expenses incurred by our group during the consolidated fiscal year totaled ¥119.159 million.」
Continued applying KIBIT across various fields, expanding solutions and developing products, and disclosed research and development expenses of ¥119.159 million. - FY2018-Q3RestatedAnnual report
「We are expanding solutions and developing products to apply our proprietary artificial intelligence engine, KIBIT, in the business intelligence, healthcare and digital communications fields.」
Continued applying KIBIT across various fields, expanding solutions and developing products. Research and development expenses were ¥129.525 million. - FY2018-Q2RestatedAnnual report
「Research and development expenses for the cumulative second-quarter period totaled ¥126.414 million.」
Continued expanding solutions and developing products to apply KIBIT across various fields, and disclosed research and development expenses of ¥126.414 million. - FY2018-Q1RestatedAnnual report
「Research and development expenses for the cumulative first-quarter period totaled ¥54.181 million.」
Continued expanding solutions and developing products to apply KIBIT in the business intelligence, digital communications and healthcare fields. Disclosed research and development expenses of ¥54.181 million. - FY2017-Q3RestatedAnnual report
「Research and development expenses for the cumulative third-quarter period totaled ¥69.486 million. We are expanding solutions and developing products to apply our proprietary artificial intelligence engine, KIBIT, in the digital marketing, healthcare and business intelligence fields.」
Continued expanding KIBIT's applications and developing new products, and disclosed research and development expenses of ¥69.486 million. - FY2017-Q2RestatedAnnual report
「Research and development expenses for the cumulative second-quarter period totaled ¥50.293 million. We are expanding solutions and developing products to apply our proprietary artificial intelligence engine, KIBIT, in the digital marketing, healthcare and business intelligence fields.」
Continued expanding KIBIT's applications and developing new products, and disclosed cumulative research and development expenses of ¥50.293 million for the quarter. - FY2017-Q1RestatedAnnual report
「Research and development expenses for the cumulative first-quarter period totaled ¥21.352 million. We are expanding solutions and developing products to apply our proprietary artificial intelligence engine, KIBIT, in the digital marketing, healthcare and business intelligence fields.」
Continued expanding KIBIT's applications and developing products, and recognized research and development expenses of ¥21.352 million for the quarter. - FY2016First statedAnnual report
「We are expanding solutions and developing products to apply our proprietary artificial intelligence engine, KIBIT, in the digital marketing, healthcare and business intelligence fields. Research and development expenses incurred by our group during the consolidated fiscal year totaled ¥91.6 million.」
Continued expanding KIBIT's applications and developing new products, and disclosed research and development expenses of ¥91.6 million for the fiscal year.